SREBF1 and Insulin resistance: The Gal OSL nanocarrier has demonstrated efficacy in mitigating liver lipid accumulation, insulin resistance, and triglyceride (TG) accumulation through the regulation of the AMPK/SIRT/FAS/SREBP1c signaling pathway.